Pharmacotherapy Publishing Inc
View my basket
Atypon Link logo

You have no access to this article

Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers


Author(s): Thomas N Kakuda | Ronald W Falcon
doi: 10.1592/phco.26.8.1060
Prev | Table of contents | Next
 
View PDF article (101 K) View references
Email this link
 What is RSS?
Trouble viewing articles as PDF?
 
  Pharmacotherapy
 
Print ISSN: 0277-0008
Volume: 26 | Issue: 8
Cover date: August 2006
Page(s): 1060-1068
 
 
  Key Words
 
drug interactions, food-drug interactions, histamine antagonists, H2 antagonists, HIV, protease inhibitors, pharmacokinetics, ranitidine, saquinavir.
 
  Abstract

Study Objectives. To assess the relative bioavailability of saquinavir after administration with ranitidine alone, ranitidine and food, and food alone; and to investigate the mechanism underlying the effects of pH and food on saquinavir absorption.

Design. Single-center, open-label, randomized, three-part crossover, pharmacokinetic pilot study.

Setting. General clinical research center in Scotland.

Subjects. Twelve healthy male volunteers.

Intervention. Each subject was given a single dose of saquinavir mesylate 600 mg with one of three randomly assigned treatments: ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, without food (treatment A); ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, with food (treatment B); and with food alone (treatment C, control). After a 7-day washout period between each of the interventions, subjects received the other two treatments.

Measurements and Main Results. Blood samples were taken serially for 24 hours after each saquinavir dose, and gastric pH was measured during the 8 hours after dosing. Adverse events were monitored throughout the study. Single doses of saquinavir were well tolerated with or without ranitidine. Of the three treatments, the highest mean maximum plasma concentration (Cmax) and area under the plasma concentration–time curve (AUC) for saquinavir occurred with treatment B; the lowest Cmax and AUC occurred with treatment A. Compared with treatment C (control), saquinavir's bioavailability was 15.9% (90% confidence interval [CI] 10–25%) after treatment A and 167% (90% CI 106–265%) after treatment B. Interindividual variability in both Cmax and AUC was slightly greater after treatments A and B than after treatment C. No correlation was found between pharmacokinetic parameters (Cmax and AUC) and gastric pH parameters, including maximum pH and pH at the time of drug delivery.

Conclusion. Plasma concentrations of saquinavir were significantly higher when the drug was administered with food and ranitidine than when it was given with food alone. However, these increases were not related to changes in gastric pH caused by ranitidine. It can be postulated that food does not increase the bioavailability of saquinavir through its effect on gastric pH.

 
  Author(s) affiliations
 
1Hoffman-La Roche Inc., Nutley, New Jersey.
2Hoffman-La Roche Inc., Nutley, New Jersey.
1Address reprint requests to Thomas N. Kakuda, Pharm.D., Tibotec, Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067
 
  This article has been cited by:
1.
 
Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects.
K Singh, L Dickinson, A Chaikan, D Back, C Fletcher, A Pozniak, G Moyle, M Nelson, B Gazzard, D Herath, M Boffito.
Clinical Pharmacology & Therapeutics |  83 |  6 |  867-872
CrossRef
2.
 
Drug Interactions between HIV Protease Inhibitors and Acid-Reducing Agents.
Ronald W Falcon, Thomas N Kakuda.
Clinical Pharmacokinetics |  47 |  2 |  75
CrossRef
3.
 
Drug interactions between proton pump inhibitors and antiretroviral drugs.
Sarah M McCabe, Patrick F Smith, Qing Ma, Gene D Morse.
Expert Opinion on Drug Metabolism & Toxicology |  3 |  2 |  197-207
CrossRef